{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T08:34:10Z","timestamp":1794818050225,"version":"4.9.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1290,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41374-019-0231-z","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T11:08:07Z","timestamp":1550056087000},"page":"958-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation"],"prefix":"10.1016","volume":"99","author":[{"given":"Rudy J.","family":"Castellani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-0172","authenticated-orcid":false,"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41374-019-0231-z_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1038\/s41374-019-0231-z_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0022-510X(89)90019-1","article-title":"The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome","volume":"89","author":"Mann","year":"1989","journal-title":"J Neurol Sci"},{"key":"10.1038\/s41374-019-0231-z_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","article-title":"Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease","volume":"349","author":"Goate","year":"1991","journal-title":"Nature"},{"key":"10.1038\/s41374-019-0231-z_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/0140-6736(91)93011-W","article-title":"Molecular classification of Alzheimer's disease","volume":"337","author":"No authors listed","year":"1991","journal-title":"Lancet"},{"key":"10.1038\/s41374-019-0231-z_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1101\/cshperspect.a024067","article-title":"Structural and chemical biology of presenilin complexes","volume":"7","author":"Johnson","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1038\/s41374-019-0231-z_bib6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","article-title":"Secreted amyloid \u03b2-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease","volume":"2","author":"Scheuner","year":"1996","journal-title":"Nat Med"},{"key":"10.1038\/s41374-019-0231-z_bib7","doi-asserted-by":"crossref","first-page":"32721","DOI":"10.1016\/S0021-9258(20)30050-8","article-title":"APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42\/43 and a beta 1-40) in familial Alzheimer's disease brain","volume":"269","author":"Tamaoka","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1038\/s41374-019-0231-z_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.410370303","article-title":"Evidence that A\u03b242 is the real culprit in alzheimer's disease","volume":"37","author":"Younkin","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib9","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1074\/jbc.270.13.7013","article-title":"Amyloid Beta protein (ABeta) in Alzheimer's disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at ABeta40 or ABeta42(43)","volume":"270","author":"Gravina","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1038\/s41374-019-0231-z_bib10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/brain\/awv006","article-title":"Rapidly progressive Alzheimer's disease features distinct structures of amyloid-\u03b2","volume":"138","author":"Cohen","year":"2015","journal-title":"Brain"},{"key":"10.1038\/s41374-019-0231-z_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ana.410380312","article-title":"Amyloid \u03b2\u2010proteins 1-40 and 1-42(43) in the soluble fraction of extra\u2010 and intracranial blood vessels","volume":"38","author":"Shinkai","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/0006-8993(88)90673-7","article-title":"Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging","volume":"474","author":"Joachim","year":"1988","journal-title":"Brain Res"},{"key":"10.1038\/s41374-019-0231-z_bib13","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0006-3495(94)80591-0","article-title":"Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths","volume":"67","author":"Snyder","year":"1994","journal-title":"Biophys J"},{"key":"10.1038\/s41374-019-0231-z_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1523\/JNEUROSCI.4849-06.2007","volume":"27","author":"Kim","year":"2007","journal-title":"J Neurosci"},{"key":"10.1038\/s41374-019-0231-z_bib15","first-page":"55","article-title":"Apolipoprotein E in Alzheimer's disease: an update","volume":"37","author":"Ai","year":"2014","journal-title":"Annu Rev Neurosci"},{"key":"10.1038\/s41374-019-0231-z_bib16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/bi00727a022","article-title":"Heterogeneity of human plasma very low density lipoproteins. separation of species differing in protein components","volume":"12","author":"Shore","year":"1973","journal-title":"Biochemistry"},{"key":"10.1038\/s41374-019-0231-z_bib17","first-page":"1034","article-title":"Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage","volume":"48","author":"Pericak-Vance","year":"1991","journal-title":"Am J Hum Genet"},{"key":"10.1038\/s41374-019-0231-z_bib18","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41374-019-0231-z_bib19","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1021\/jm3008618","article-title":"Small-Molecule structure correctors target abnormal protein structure and function: Structure corrector rescue of apolipoprotein E4-associated neuropathology","volume":"55","author":"Mahley","year":"2012","journal-title":"J Med Chem"},{"key":"10.1038\/s41374-019-0231-z_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrn2620","article-title":"and its receptors in Alzheimer's disease: pathway, pathogenesis and therapy","volume":"10","author":"Bu","year":"2009","journal-title":"Nat Rev Neurosc"},{"key":"10.1038\/s41374-019-0231-z_bib21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and A\u03b2 in Alzheimer's disease: accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"key":"10.1038\/s41374-019-0231-z_bib22","doi-asserted-by":"crossref","first-page":"50380","DOI":"10.1074\/jbc.M204898200","article-title":"Apolipoprotein E4 forms a molten globule: A potential basis for its association with disease","volume":"277","author":"Morrow","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1038\/s41374-019-0231-z_bib23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1038\/s41374-019-0231-z_bib24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/hmg\/3.4.569","article-title":"Apolipoprotein-E, Epsilon-4 Allele as a major risk factor for sporadic early and late-onset forms of alzheimers-disease\u2014analysis of the 19Q13.2 chromosomal region","volume":"3","author":"Chartier-Hariln","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1038\/s41374-019-0231-z_bib25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.neuron.2012.11.020","article-title":"Apolipoprotein E Sets the stage: response to injury triggers neuropathology","volume":"76","author":"Mahley","year":"2012","journal-title":"Neuron"},{"key":"10.1038\/s41374-019-0231-z_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-neuro-071013-014300","article-title":"Apolipoprotein E in Alzheimer's Disease: an update","volume":"37","author":"Yu","year":"2014","journal-title":"Annu Rev Neurosci"},{"key":"10.1038\/s41374-019-0231-z_bib27","doi-asserted-by":"crossref","first-page":"10571","DOI":"10.1021\/bi9626362","article-title":"Interaction of nascent Apoe2, Apoe3, and Apoe4 isoforms expressed in mammalian cells with amyloid peptide\u202fbeta (1\u201340). relevance to Alzheimer's disease","volume":"36","author":"Aleshkov","year":"1997","journal-title":"Biochemistry"},{"key":"10.1038\/s41374-019-0231-z_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of A\u03b2","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"10.1038\/s41374-019-0231-z_bib29","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1096\/fj.10-175976","article-title":"High ability of apolipoprotein E4 to stabilize amyloid- peptide oligomers, the pathological entities responsible for Alzheimer's disease","volume":"25","author":"Cerf","year":"2011","journal-title":"FASEB J"},{"key":"10.1038\/s41374-019-0231-z_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11682-013-9272-x","article-title":"Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction","volume":"8","author":"Ungar","year":"2014","journal-title":"Brain Imaging Behav"},{"key":"10.1038\/s41374-019-0231-z_bib31","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1073\/pnas.95.18.10914","article-title":"Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females","volume":"95","author":"Raber","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41374-019-0231-z_bib32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jama.279.10.751","article-title":"The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics","volume":"279","author":"Tang","year":"1998","journal-title":"JAMA"},{"key":"10.1038\/s41374-019-0231-z_bib33","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1038\/s41374-019-0231-z_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0694-180","article-title":"Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease","volume":"7","author":"Corder","year":"1994","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-019-0231-z_bib35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","article-title":"Apolipoprotein E as a therapeutic target in alzheimer's disease: a review of basic research and clinical evidence","volume":"30","author":"Yamazaki","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1038\/s41374-019-0231-z_bib36","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/hmg\/dds296","article-title":"Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease","volume":"21","author":"Cruchaga","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1038\/s41374-019-0231-z_bib37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2006-9S317","article-title":"Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal","volume":"9","author":"Hardy","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1038\/s41374-019-0231-z_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1038\/s41374-019-0231-z_bib40","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1074\/jbc.271.8.4077","article-title":"Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains","volume":"271","author":"Kuo","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1038\/s41374-019-0231-z_bib41","doi-asserted-by":"crossref","first-page":"14745","DOI":"10.1073\/pnas.0905127106","article-title":"Structure-neurotoxicity relationships of amyloid -protein oligomers","volume":"106","author":"Ono","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41374-019-0231-z_bib42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-\u03b2 protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"key":"10.1038\/s41374-019-0231-z_bib43","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1073\/pnas.0811698106","article-title":"Oligomeric amyloid associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques","volume":"106","author":"Koffie","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41374-019-0231-z_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/NEN.0b013e318217a118","article-title":"Brain oligomeric \u03b2-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein\/tau transgenic mice","volume":"70","author":"Darocha-Souto","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.23748","article-title":"Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls","volume":"73","author":"Esparza","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuron.2014.02.027","article-title":"Soluble A\u03b2 oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes","volume":"82","author":"Hong","year":"2014","journal-title":"Neuron"},{"key":"10.1038\/s41374-019-0231-z_bib47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00702-017-1820-x","article-title":"Amyloid \u03b2 oligomers (A\u03b2Os) in Alzheimer's disease","volume":"125","author":"Mroczko","year":"2018","journal-title":"J Neural Transm"},{"key":"10.1038\/s41374-019-0231-z_bib48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic A\u03b2 oligomer and Alzheimer's disease: An emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.1038\/s41374-019-0231-z_bib49","doi-asserted-by":"crossref","first-page":"14488","DOI":"10.1523\/JNEUROSCI.3088-11.2011","article-title":"Soluble A beta seeds are potent inducers of cerebral beta -amyloid deposition","volume":"31","author":"Langer","year":"2011","journal-title":"J Neurosci"},{"key":"10.1038\/s41374-019-0231-z_bib50","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","article-title":"Seeding \u201cone-dimensional crystallization\u201d of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?","volume":"73","author":"Jarrett","year":"1993","journal-title":"Cell"},{"key":"10.1038\/s41374-019-0231-z_bib51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1126\/science.1105850","article-title":"Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's \u03b2-amyloid fibrils","volume":"307","author":"Petkova","year":"2005","journal-title":"Science"},{"key":"10.1038\/s41374-019-0231-z_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00401-011-0912-1","article-title":"The presence of A\u03b2 seeds, and not age per se, is critical to the initiation of A\u03b2 deposition in the brain","volume":"123","author":"Hamaguchi","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1038\/s41374-019-0231-z_bib53","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00401-016-1565-x","article-title":"Dura mater is a potential source of Abeta seeds","volume":"131","author":"Kovacs","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1038\/s41374-019-0231-z_bib54","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.neurobiolaging.2007.04.026","article-title":"Tauopathy in human and experimental variant Creutzfeldt-Jakob disease","volume":"29","author":"Giaccone","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1038\/s41374-019-0231-z_bib55","first-page":"183","article-title":"Rapidly progressive Alzheimer's disease in two distinct autopsy cohorts","volume":"86","author":"Pillai","year":"2016","journal-title":"Neurology"},{"key":"10.1038\/s41374-019-0231-z_bib56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ana.410390613","article-title":"Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease","volume":"39","author":"Parchi","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W","article-title":"Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects","volume":"46","author":"Parchi","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jalz.2016.09.002","article-title":"Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans","volume":"13","author":"Mez","year":"2017","journal-title":"Alzheimer's Dement"},{"key":"10.1038\/s41374-019-0231-z_bib59","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-019-0231-z_bib60","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","article-title":"Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study","volume":"10","author":"Murray","year":"2001","journal-title":"Lancet Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12168","article-title":"Amyloid-\u00df-directed immunotherapy for Alzheimer's disease","volume":"275","author":"Lannfelt","year":"2014","journal-title":"J Intern Med"},{"key":"10.1038\/s41374-019-0231-z_bib62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","article-title":"A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease","volume":"76","author":"Karran","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib63","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1038\/s41374-019-0231-z_bib64","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JAD-179901","article-title":"Clinical trials for disease-modifying therapies in alzheimer's disease: a primer, lessons learned, and a blueprint for the future","volume":"64","author":"Cummings","year":"2018","journal-title":"J Alzheimer's Dis"},{"key":"10.1038\/s41374-019-0231-z_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"10.1038\/s41374-019-0231-z_bib66","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt246","article-title":"Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease","volume":"6","author":"Lannfelt","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1038\/s41374-019-0231-z_bib67","doi-asserted-by":"crossref","first-page":"18325","DOI":"10.1074\/jbc.M117.801514","article-title":"Mechanisms of recognition of amyloid-\u03b2 (A\u03b2) monomer, oligomer, and fibril by homologous antibodies","volume":"292","author":"Zhao","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1038\/s41374-019-0231-z_bib68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2010.06.010","article-title":"Measurement of anti-beta amyloid antibodies in human blood","volume":"227","author":"Szabo","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1038\/s41374-019-0231-z_bib69","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1038\/s41374-019-0231-z_bib70","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-017-0850-1","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials","volume":"17","author":"Abushouk","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib71","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/JAD-151065","article-title":"Biomarker exposure-response analysis in mild-to-moderate Alzheimer's Disease trials of bapineuzumab","volume":"53","author":"Russu","year":"2016","journal-title":"J Alzheimer's Dis"},{"key":"10.1038\/s41374-019-0231-z_bib72","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3233\/JAD-150448","article-title":"Changes in brain volume with bapineuzumab in mild to moderate Alzheimer's disease","volume":"49","author":"Novak","year":"2015","journal-title":"J Alzheimer's Dis"},{"key":"10.1038\/s41374-019-0231-z_bib73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer's disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1038\/s41374-019-0231-z_bib74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer's Dement"},{"key":"10.1038\/s41374-019-0231-z_bib75","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A antibody alters CNS and plasma A clearance and decreases brain A burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41374-019-0231-z_bib76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's Disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/s41374-019-0231-z_bib77","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer's Disease mice","volume":"76","author":"DeMattos","year":"2012","journal-title":"Neuron"},{"key":"10.1038\/s41374-019-0231-z_bib78","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The Amyloid-\u03b2 oligomer hypothesis: beginning of the third decade","volume":"64","author":"Cline","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1038\/s41374-019-0231-z_bib79","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.57.5.801","article-title":"Reduced levels of amyloid beta-peptide antibody in Alzheimer disease","volume":"57","author":"Du","year":"2001","journal-title":"Neurology"},{"key":"10.1038\/s41374-019-0231-z_bib80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ana.10253","article-title":"Human antibodies against amyloid peptide: a potential treatment for Alzheimer's Disease","volume":"52","author":"Dodel","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib81","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0b013e3181ae7aaf","article-title":"IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders","volume":"73","author":"Fillit","year":"2009","journal-title":"Neurology"},{"key":"10.1038\/s41374-019-0231-z_bib82","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/brain\/awg191","article-title":"Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity","volume":"126","author":"Du","year":"2003","journal-title":"Brain"},{"key":"10.1038\/s41374-019-0231-z_bib83","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/s41374-019-0231-z_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-7-90","article-title":"Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease","volume":"7","author":"Magga","year":"2010","journal-title":"J Neuroinflamm"},{"key":"10.1038\/s41374-019-0231-z_bib85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neulet.2008.08.083","article-title":"Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid antibodies in a transgenic mouse model of Alzheimer's disease","volume":"449","author":"Bacher","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1038\/s41374-019-0231-z_bib86","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology"},{"key":"10.1038\/s41374-019-0231-z_bib87","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.jasms.2010.05.007","article-title":"Investigation of the noncovalent interactions between anti-amyloid agents and amyloid \u03b2 peptides by ESI-MS","volume":"21","author":"Martineau","year":"2010","journal-title":"J Am Soc Mass Spectrom"},{"key":"10.1038\/s41374-019-0231-z_bib88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease\u2014a randomized, double-blind, placebo-controlled, multi-centre study (the alphase study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.1038\/s41374-019-0231-z_bib89","first-page":"219","article-title":"Clinical benefits of tramiprosate in Alzheimer's Disease are associated with higher number of APOE4 Alleles: the \u201c APOE4 gene- dose effect","volume":"33","author":"Abushakra","year":"2016","journal-title":"J Prev Alz Dis"},{"key":"10.1038\/s41374-019-0231-z_bib90","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A Phase 3 trial of semagacestat for treatment of Alzheimer's Disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/s41374-019-0231-z_bib91","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.wnf.0000167360.27670.29","article-title":"Safety, tolerability, and changes in amyloid\u202fbeta concentrations after administration of a\u202fgamma-secretase inhibitor in volunteers","volume":"28","author":"Siemers","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1038\/s41374-019-0231-z_bib92","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.celrep.2017.09.032","article-title":"Semagacestat Is a Pseudo-Inhibitor of \u03b3-Secretase","volume":"21","author":"Tagami","year":"2017","journal-title":"Cell Rep"},{"key":"10.1038\/s41374-019-0231-z_bib94","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1074\/jbc.M111.305227","article-title":"First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms","volume":"287","author":"Borgegard","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1038\/s41374-019-0231-z_bib95","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/19083","article-title":"A presenilin-1-dependent \u03b3-secretase-like protease mediates release of notch intracellular domain","volume":"398","author":"De Strooper","year":"1999","journal-title":"Nature"},{"key":"10.1038\/s41374-019-0231-z_bib96","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI18162","article-title":"NSAIDs and enantiomers of flurbiprofen target g-secretase and lower Ab42 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1038\/s41374-019-0231-z_bib97","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1021\/jm0502541","article-title":"Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion","volume":"48","author":"Peretto","year":"2005","journal-title":"J Med Chem2"},{"key":"10.1038\/s41374-019-0231-z_bib98","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1038\/s41374-019-0231-z_bib99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the \u03b2 secretase BACE1 for Alzheimer's disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1038\/s41374-019-0231-z_bib100","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","article-title":"Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide derivative verubecestat (MK-8931)\u2014A\u03b2-Site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's Disease","volume":"59","author":"Scott","year":"2016","journal-title":"J Med Chem"},{"key":"10.1038\/s41374-019-0231-z_bib101","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS b-Amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1038\/s41374-019-0231-z_bib102","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","article-title":"AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer's Disease","volume":"55","author":"Cebers","year":"2016","journal-title":"J Alzheimer's Dis"},{"key":"10.1038\/s41374-019-0231-z_bib103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1038\/s41374-019-0231-z_bib104","first-page":"169","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement NY"},{"key":"10.1038\/s41374-019-0231-z_bib105","first-page":"255","article-title":"Clinical development of aducanumab, an anti-A\u03b2 human monoclonal antibody being investigated for the treatment of early Alzheimer's disease","volume":"4","author":"Budd Haeberlein","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1038\/s41374-019-0231-z_bib106","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1038\/s41374-019-0231-z_bib107","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1038\/s41374-019-0231-z_bib108","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/s41374-019-0231-z_bib109","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"10.1038\/s41374-019-0231-z_bib110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer's Re Ther"},{"key":"10.1038\/s41374-019-0231-z_bib111","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-018-1134-4","article-title":"The A\u03b2 protofibril selective antibody mAb158 prevents accumulation of A\u03b2 in astrocytes and rescues neurons from A\u03b2-induced cell death","volume":"15","author":"Sollvander","year":"2018","journal-title":"J Neuroinflamm"},{"key":"10.1038\/s41374-019-0231-z_bib112","article-title":"Alzheimer's disease, more on BAN2401, unfortunately","author":"Lowe","year":"2018","journal-title":"Sci Trans Med, Blog"},{"key":"10.1038\/s41374-019-0231-z_bib113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/19336896.2015.1123371","article-title":"Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease","volume":"10","author":"Cohen","year":"2016","journal-title":"Prion"},{"key":"10.1038\/s41374-019-0231-z_bib114","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","article-title":"Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective fro 2010\u20135","volume":"26","author":"Mehta","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1038\/s41374-019-0231-z_bib115","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1126\/science.aau0437","article-title":"Alzheimer's disease: the right drug, the right time","volume":"362","author":"Golde","year":"2018","journal-title":"Science"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0231-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0231-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722026034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722026034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0231-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:50:45Z","timestamp":1758397845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722026034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0023683722026034"],"URL":"https:\/\/doi.org\/10.1038\/s41374-019-0231-z","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41374-019-0231-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}